3 results
Not approvedWill not start
Main objective:To improve the functional neurological outcome of patients, as measured on the Raschbuilt Overall Disability Scale (RODS) for inflammatory neuropathies (iRODS) with Zanubrutinib in combination with standard treatment with Rituximab or…
Approved WMORecruiting
This study has been transitioned to CTIS with ID 2024-511267-28-00 check the CTIS register for the current data. To evaluate the long-term safety of zanubrutinib in patients with B-cell cancers who participated in a BeiGene parent study for…
Approved WMOCompleted
Primary:• To compare the efficacy of zanubrutinib (also known as BGB-3111) versus ibrutinib as measured by overall response rate determined by investigator assessment Secondary:• To compare the efficacy of zanubrutinib versus ibrutinib as measured…